Literature DB >> 19943768

Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer.

Seyed Mohammad Taghdisi1, Khalil Abnous, Fatemeh Mosaffa, Javad Behravan.   

Abstract

Application of daunorubicin in treatment of leukemia has been limited for its side effects like cardiotoxicity. Specific delivery of chemotherapy drugs is an important factor in decreasing their side effects. In this study, sgc8, an aptamer for protein tyrosine kinase-7 (PTK7), was used for specific delivery of daunorubicin to Molt-4 cells (PTK7(+)). Flow cytometric experiments showed that aptamer-daunorubicin complex was internalized effectively to Molt-4 cells (PTK7(+)), but not to U266 cells (PTK7(-)). This fact was confirmed by less cytotoxicity of aptamer-drug complex in U266 cells in compare to daunorubicin alone. No significant change in viability between daunorubicin and aptamer-daunorubicin complex treated Molt4 cells was observed. In conclusion, sgc8-daunorubicin complex is introduced as a simple and efficient system for targeted delivery of drug to acute lymphoblastic leukemia T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19943768     DOI: 10.3109/10611860903434050

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  16 in total

Review 1.  Cell-specific aptamer-mediated targeted drug delivery.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Oligonucleotides       Date:  2010-12-23

Review 2.  Tumor-targeted drug delivery with aptamers.

Authors:  Y Zhang; H Hong; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 3.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

4.  Targeted Delivery of Epirubicin to Cancer Cells by Polyvalent Aptamer System in vitro and in vivo.

Authors:  Rezvan Yazdian-Robati; Mohammad Ramezani; Seyed Hamid Jalalian; Khalil Abnous; Seyed Mohammad Taghdisi
Journal:  Pharm Res       Date:  2016-06-09       Impact factor: 4.200

Review 5.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

6.  Cell-specific aptamers as emerging therapeutics.

Authors:  Cindy Meyer; Ulrich Hahn; Andrea Rentmeister
Journal:  J Nucleic Acids       Date:  2011-08-28

Review 7.  Generating aptamers by cell-SELEX for applications in molecular medicine.

Authors:  Mao Ye; Jun Hu; Minyuan Peng; Jing Liu; Jun Liu; Huixia Liu; Xielan Zhao; Weihong Tan
Journal:  Int J Mol Sci       Date:  2012-03-12       Impact factor: 6.208

8.  Amorphous calcium phosphate nanoparticles could function as a novel cancer therapeutic agent by employing a suitable targeted drug delivery platform.

Authors:  Milad Pourbaghi-Masouleh; Vahid Hosseini
Journal:  Nanoscale Res Lett       Date:  2013-10-30       Impact factor: 4.703

Review 9.  Aptamers: Cutting edge of cancer therapies.

Authors:  Sarah Shigdar; Brett Schrand; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2021-06-17       Impact factor: 12.910

Review 10.  Aptamers for Targeted Drug Delivery.

Authors:  Partha Ray; Rebekah R White
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.